Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Puma Biotechnology Inc. Stock

Price
Target price
€4.54

€4.54

-0.980%
-0.044
-0.980%
€10.00

€10.00

 
Buy 1 Sell 0
Buy 1
Sell 0
25.04.24 / Tradegate WKN: A1J643 / Name: Puma Biotechnology / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
€10.00
26.03.24
-14.26%
buy
Show more
Your prediction
Pros and Cons of Puma Biotechnology Inc. in the next few years
Wizard

Puma Biotechnology Inc. Stock

Puma Biotechnology Inc. shows a slight decrease today, losing -€0.044 (-0.980%) compared to yesterday.
The community is currently still undecided about Puma Biotechnology Inc. with 1 Buy predictions and 0 Sell predictions.
Based on the current price of 4.54 € the target price of 10 € shows a potential of 120.07% for Puma Biotechnology Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Puma Biotechnology Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Puma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.

Pros and Cons of Puma Biotechnology Inc. in the next few years

Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Puma Biotechnology Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Puma Biotechnology Inc. -0.980% 0.754% -7.736% 86.996% 16.364% -44.558% -
Ardelyx Inc. 6.810% -0.366% -11.361% 47.951% 3.668% -1.770% -
Salarius Pharmaceuticals Inc. -2.830% -3.738% -2.830% -71.389% -25.766% -98.474% -99.994%
Brainstorm Cell -30.000% -29.447% -33.143% -87.283% 51.293% -87.897% -
Register To Post

News

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter

BusinessWire_EN 
0 18.04.24
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement

BusinessWire_EN 
0 03.04.24
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application

BusinessWire_EN 
0 20.03.24